drugset
drugset / Trial / NCT01888081

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

NCT01888081 ↗

Phase 1/2 Terminated 2 enrolled Virogen Biotechnology Inc. University of Louisville · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range from 8-16 months.

Timeline

Start
2014-02
Primary completion
2020-12
Completion
—

Outcome

Outcome not reported

Stopped: “Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Resimmune® Protein / enzyme biologic — —

Indications

melanoma